BCX4208 (PNP Inhibitor)

Structure of PNP enzyme

BCX4208 is a next generation purine nucleoside phosphorylase (PNP) inhibitor with the potential for once-a day dosing suitable for chronic administration. A recent study has shown that BCX4208 may have utility in diseases dependent on T-cells, B-cells or uric acid. With its novel mechanism of action, BCX4208 has the potential to address unmet medical needs across a broad spectrum of inflammatory diseases.

In September 2009, BioCryst announced the initiation of a Phase 2 study in gout.

About Gout

Gout is an inflammatory arthritis characterized by the presence of monosodium urate crystals in synovial fluid leukocytes and is always associated with hyperuricemia, or excessive concentrations of uric acid in the blood, during the course of the diseases. Monosodium urate crystals and crystal aggregates activate humoral and cellular inflammatory components leading an intense inflammatory response.

Clinical Trials

To learn more about our current studies visit our Clinical Trials page or visit clinicaltrials.gov.

Resources

For more information about gout visit the Center for Disease Control and Prevention (CDC): 
http://www.cdc.gov/arthritis/basics/gout.htm